Trident Lifeline Converts 135,000 Warrants Worth ₹2.69 Crores on December 27

Trident Lifeline Limited announced the successful conversion of 135,000 warrants into equity shares on December 27, 2025, generating proceeds of ₹2.69 crores. The Board of Directors approved the allotment at their meeting held on December 27, 2025, which commenced at 2:00 PM and concluded at 2:30 PM.

Warrant Conversion Details

The conversion involved two warrant holders who exercised their option to convert warrants at an issue price of ₹266.00 per share, comprising a face value of ₹10.00 and premium of ₹256.00 per share:

Warrant Holder:	Warrants Converted	Amount Received (₹)
Maniya H Desai:	88,200	1,75,95,900
Rupaben Chetan Jariwala:	46,800	93,36,600
Total:	135,000	2,69,32,500

Updated Capital Structure

Following the warrant conversion, the company's issued, subscribed and paid-up equity share capital increased to ₹11.93 crores, consisting of 11,933,000 equity shares of ₹10.00 face value each. The newly allotted shares rank pari-passu with existing equity shares of the company.

Capital Structure:	Updated Position
Paid-up Capital:	₹11.93 crores
Total Equity Shares:	11,933,000
Face Value per Share:	₹10.00

Original Warrant Issue Background

The company had originally allotted 994,200 fully convertible warrants in June 2025 at an issue price of ₹266.00 each on preferential basis to promoter and non-promoter entities. Under SEBI regulations, warrant holders initially paid 25% of the issue price (₹66.50 per warrant) as subscription price, with the remaining 75% (₹199.50 per warrant) payable upon conversion.

Regulatory Compliance

The warrant conversion process adheres to SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and complies with disclosure requirements under Regulation 30 of SEBI Listing Regulations. The company has fulfilled all regulatory obligations including SEBI circulars dated July 13, 2023, November 11, 2024, and December 31, 2024.

Regulatory Framework:	Compliance Status
SEBI ICDR Regulations 2018:	Fully Compliant
SEBI Listing Regulations:	Disclosed under Regulation 30
Warrant Exercise Period:	Within prescribed timeline

The conversion represents continued confidence from warrant holders in the pharmaceutical company's growth prospects, with substantial warrant positions remaining outstanding for potential future conversions.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+7.88%	+6.38%	+0.40%	+10.45%	+13.21%	+193.11%

Trident Lifeline Limited , a pharmaceutical company, has announced another significant warrant conversion following its board meeting held on December 16, 2025, further strengthening its capital base.

Latest Warrant Conversion

The company's board has approved the conversion of 1,00,200 warrants into equity shares, marking the second major conversion since the original warrant allotment. Key details of the latest transaction include:

Parameter:	Details
Warrants Converted:	1,00,200
Conversion Price per Share:	₹266.00
Amount Raised:	₹1,99,89,900
New Paid-up Capital:	₹11,79,80,000
Total Equity Shares Outstanding:	1,17,98,000

Warrant Holders and Distribution

The conversion involved two key stakeholders with the following allocation:

Warrant Holder:	Warrants Applied:	Shares Allotted:	Amount Received:
Hardik Desai Family Trust:	1,000	1,000	₹1,99,500
Maniya H Desai:	99,200	99,200	₹1,97,90,400

Each warrant was convertible into one fully paid-up equity share with a face value of ₹10.00. The conversion price of ₹266.00 per share includes a premium of ₹256.00.

Updated Capital Structure

Following this conversion, Trident Lifeline's capital structure has been significantly updated:

Metric:	Current Status
Paid-up Equity Share Capital:	₹11,79,80,000
Total Equity Shares:	1,17,98,000
Remaining Warrants Pending:	8,94,000
Face Value per Share:	₹10.00

Regulatory Compliance

The warrant conversion was conducted in accordance with SEBI regulations, including the Issue of Capital and Disclosure Requirements Regulations, 2018. The company has fulfilled all regulatory requirements under Regulation 30 of the Listing Regulations and various SEBI circulars.

Implications for Investors

The substantial number of remaining warrants (8,94,000) indicates potential for further capital expansion. The new equity shares rank pari-passu with existing equity shares, maintaining equal rights for all shareholders. This conversion demonstrates continued confidence from key stakeholders in the company's growth prospects while providing additional capital for business operations.